Neurotrack

Neurotrack is transforming the diagnosis of Alzheimer’s disease. Through a safe and non-invasive test, its technology can predict the risk of developing mild cognitive impairment and Alzheimer’s disease years before symptoms occur. Conceived at Emory University and validated by a 5-year study funded by the National Institutes of Health (NIH), it will give pharmaceutical companies better tools to recruit patients for clinical trials, leading to the development of life-saving drugs.

Neurotrack is backed by Founders Fund and Social + Capital, and was the winner of more than $7M in grants from the NIH. It was named Best Health Company at SXSW, DEMO, and participated in the Rock Health accelerator.

Company Growth (employees)
Type
Private
HQ
Palo Alto, US
Founded
2012
Size (employees)
17 (est)+7%
Neurotrack was founded in 2012 and is headquartered in Palo Alto, US

Neurotrack Office Locations

Neurotrack has office in Palo Alto
Palo Alto, US

Neurotrack Metrics

Neurotrack Summary

Founding Date

2012

Total Funding

$9.6 m

Latest funding size

$6.5 m

Time since last funding

about 1 year

Investors

We estimate that Neurotrack's latest funding round in January 2016 was $6.5 m. In total, Neurotrack has raised $9.6 m
We estimate that Neurotrack's current employees are approximately 42% female and 58% male.

Neurotrack Online Presence

Neurotrack News

Neurotrack Company Life

You may also be interested in